Rare disease biopharma companies weigh in on FDA’s new innovation hub

As­traZeneca’s Alex­ion, Bridge­Bio, Bio­Marin, Ul­tragenyx and oth­ers, in­clud­ing Sen. Bob Casey (D-PA), re­cent­ly weighed in on the de­tails of a new cross-cut­ting FDA col­lab­o­ra­tion hub …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.